Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC xenografts...Ganetespib treatment at its MTD of 150 mg/kg weekly resulted in a similar degree (27%) of tumor shrinkage...Animals bearing H3122 xenografts were dosed intravenously with ganetespib at 50 mg/kg once a week (Fig. 2A). This regimen resulted in significant tumor growth inhibition [treatment vs. control (T/C) value of 21%] over a 3-week period. Treating at MTD (data not shown) or splitting the dose into 2-consecutive-day dosing of 25 mg/kg each week resulted in a minor improvement in efficacy (T/C value of 10%) and disease stabilization...